Australia's largest stock trading and investment forum Australia's #1 stock forum

RAP raptor resources limited

0.00%

20.5¢

2020 The Year Of RAP, page-1109

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 1109 Last

Share
Profile

Follow
Red bar

2,574 Posts.

4962

26/02/20

12:23

Post #: 43160881
Share

Originally posted by Red bar ↑

Exactly! ResApp could play a vital role in identifying the seriously ill from this virus early and potentially save their lives as they could seek medical help in a more timely manner. It's a no brainer to get this technology out to the community as soon as possible!!

Pediatric clinical study 2016:

"The research team also performed a preliminary evaluation of the algorithms’ ability to separate bacterial and atypical pneumonia from viral pneumonia. These preliminary results demonstrated that ResApp’s algorithms could achieve accuracy of between 89% and 92% for the separation of these different types of pneumonia."

Also more groundbreaking news from the adult clinical study from December 2017:

" Demonstrated, for the first time, accurate differential diagnosis of community-acquired pneumonia and acute asthma within an adult intended use population (those experiencing
a broad range of respiratory illness) at 90-91% positive percent agreement and 88% negative percent agreement with clinical diagnosis".

The reason why the death toll is rising from the Corona virus is not from the upper tract respiratory symptoms. The unfortunate people that are passing away from this virus are the ones that develop lower tract infections that lead to pneumonia. As our company has proven in the quotes above.

"Coronavirus disease (COVID-19) is characterized by mild symptoms including a runny nose, sore throat, cough, and fever. Illness can be more severe for some people and can lead to pneumonia or breathing difficulties.
More rarely, the disease can be fatal. Older people, and people with other medical conditions (such as asthma, diabetes, or heart disease), may be more vulnerable to becoming severely ill."

Granted our technology in the US for pneumonia identification is lagging due to the unfortunate percentage outcomes from the SmartCough - C2 study for the reasons already known to the market. Now that many more people are suffering from pneumonia a retrial should be considered urgently in the U.S. to prove our technology. Visits to the ED Ward were extremely low and only made up a small percentage of the total number of test subjects presented within the study in the US. Times have changed now due to this coronavirus. A small-scale study should be urgently considered! Europe and Australia different story for pneumonia we achieved excellent results and we should push it through NOW...

Cheers

Red bar

Expand

By the way folks just to clarify when I say a small-scale study should be conducted I'm only talking about for pneumonia in the US. I believe the other results excluding bronchitis and croup were good and good is all we need to be passed by the FDA for the indications submitted. Remember the percentage outcomes are up there with stethoscopes and X-rays accuracy. There is a strong chance of ResApp obtaining de Novo FDA clearance. If our medical software has denovo clearance then all future clearances will be 510K cleared. A much less strenuous process...

Cheers

Red bar

RAP Price at posting: 20.0¢ Sentiment: Buy Disclosure: Held
12 Upvote

0 Great analysis

Reply

Top Stories

GLF

Gemlife used the ASX's new IPO fast-track. Is this the start of a new cycle?

Listen: HotCopper Wire Podcast 016 – FY25 ended up not so bad... but Trump unpause is coming

Trump chides Powell as Goldman call for calm. The RBA must be nervous

ASX Market Close: Local bourse dips red as CBA profit takers swoop

CCO

The Calmer Co FY25 revenue hits $8 million, up 86% on FY24

First 1109 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

SPONSORED BY